Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: A histopathologic and immunohistochemical study

Journal of Cutaneous Pathology

Volumn 41, Issue 5, 2014, Pages 417-426

  Llamas Velasco, Mar ^a   Fraga, Javier ^a   Kutzner, Heinz ^b   Steegmann, Juan Luis ^a   García Diez, Amaro ^a   Requena, Luis ^b  

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^b Department of Pathology Instituto de Investigaciõn Sanitaria de la Princesa ^*  (Spain)

Author keywords

chronic myelogenous leukemia; immunohistochemistry; Melan A; vitiligo

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; IMATINIB; MELANIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HUMAN; HYPOPIGMENTATION; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MELANOCYTE; MIDDLE AGED; PATHOLOGY; SKIN PIGMENTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HUMANS; HYPOPIGMENTATION; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MELANINS; MELANOCYTES; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SKIN PIGMENTATION;

EID: 84899524635     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12298     Document Type: Article

References (32)

1. Gebhardt C, Averbeck M, Paasch U, et al. A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy. Arch Dermatol 2009; 145: 571.
2. Raanani P, Goldman JM, Ben-Bassat I,. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 2002; 20: 869.
3. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201.
4. Brazzelli V, Prestinari F, Barbagallo T, et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol 2007; 21: 384.
5. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M,. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98: 2483.
6. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW,. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003; 120: 911.
7. Leong KW, Lee TC, Goh AS,. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2004; 100: 2486.
8. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G,. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005; 74: 121.
9. Sharma A, Vora A, Bhutani M,. Generalized hypopigmentation due to imatinib: a fairness boon? Indian J Dermatol Venereol Leprol 2005; 71: 45.
10. Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006; 313: 521.
11. Hendi A, Wada DA, Jacobs MA, et al. Melanocytes in nonlesional sun-exposed skin: a multicenter comparative study. J Am Acad Dermatol 2011; 65: 1186.
12. Hendi A, Brodland D, Zitelli JA,. Melanocytic hyperplasia in sun-exposed skin has been defined. Dermatol Surg 2011; 37: 550.
13. Madden K, Forman SB, Elston D,. Quantification of melanocytes in sun-damaged skin. J Am Acad Dermatol 2011; 64: 548.
14. Anbar TS, El-Sawy AE, Attia SK, et al. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study. Photodermatol Photoimmunol Photomed 2012; 28: 17.
15. Singh ZN, Tretiakova MS, Shea CR, Petronic-Rosic VM,. Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod Pathol 2006; 19: 1255.
16. Kim J, Taube JM, McCalmont TH, Glusac EJ,. Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. J Cutan Pathol 2011; 38: 775.
17. Cario-Andre M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A,. Imatinib mesylate inhibits melanogenesis in vitro. Br J Dermatol 2006; 155: 493.
18. Cerchione C, Fabbricini R, Pane F, Luciano L,. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. Leuk Res 2009; 33: e104.
19. Cario-Andre M, Pain C, Gauthier Y, Casoli V, Taieb A,. In vivo and in vitro evidence of dermal fibroblasts influence on human epidermal pigmentation. Pigment Cell Res 2006; 19: 434.
20. McPartlin S, Leach M,. Loss of skin pigment caused by imatinib therapy. Br J Haematol 2005; 129: 448.
21. Legros L, Cassuto JP, Ortonne JP,. Imatinib mesilate (Gleevec): a systemic depigmenting agent for extensive vitiligo? Br J Dermatol 2005; 153: 691.
22. Han H, Yu YY, Wang YH,. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. J Am Acad Dermatol 2008; 59 (5 Suppl): S80.
23. Mariani S, Abruzzese E, Basciani S, et al. Reversible hair depigmentation in a patient treated with imatinib. Leuk Res 2011; 35: e64.
24. McPherson T, Sherman V, Turner R,. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 2009; 23: 82.
25. Li CC, Malik SM, Blaeser BF, et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol 2012; 6: 290.
26. Kang WH, Yoon KH, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002; 146: 228.
27. Kang HY, Hwang JS, Lee JY, et al. The dermal stem cell factor and c-kit are overexpressed in melasma. Br J Dermatol 2006; 154: 1094.
28. Beyer C, Distler JH,. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim Biophys Acta 2013; 1832: 897.
29. Hahn O, Stadler W,. Sorafenib. Curr Opin Oncol 2006; 18: 615.
30. Minami-Hori M, Ishida-Yamamoto A, Komatsu S, Iiduka H,. Transient perforating folliculitis induced by sorafenib. J Dermatol 2010; 37: 833.
31. Llamas-Velasco M, Steegmann J, Carrascosa R, Fraga J, García-Diez A, Requena L,. Perforating folliculitis in a patient treated with Nilotinib: a further evidence of PDGF-R involvement in human hair follicle cycle. Am J Dermatopathol 2013 [Epub 22 Apr].
32. Weger N, Schlake T,. Igf-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol 2005; 125: 873.